Array BioPharma (ARRY) PT Lifted to $15 at Piper Jaffray; Proforma Cash Of $222 Million To File NDAs

February 4, 2015 9:16 AM

Piper Jaffray analyst Edward Tenthoff boosted his price target on Overweight-rated Array BioPharma (NASDAQ: ARRY) to $15.00 (from $9.00) with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found